Alnylam Pharmaceuticals Inc (ALNY.OQ)
ALNY.OQ on NASDAQ Stock Exchange Global Select Market
83.08USD
4:26pm BST
83.08USD
4:26pm BST
Change (% chg)
$0.92 (+1.12%)
$0.92 (+1.12%)
Prev Close
$82.16
$82.16
Open
$81.72
$81.72
Day's High
$83.98
$83.98
Day's Low
$81.56
$81.56
Volume
43,905
43,905
Avg. Vol
319,590
319,590
52-wk High
$124.15
$124.15
52-wk Low
$60.28
$60.28
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2019 | Mar '19 | 33.29 | -1.726 |
| FY 2018 | Dec '18 | 21.03 | -2.092 |
| Sep '18 | 2.07 | -2.434 | |
| Jun '18 | 29.91 | -1.627 | |
| Mar '18 | 21.90 | -1.420 | |
| FY 2017 | Dec '17 | 37.92 | -1.479 |
| Sep '17 | 17.10 | -1.339 | |
| Jun '17 | 15.93 | -1.344 | |
| Mar '17 | 18.96 | -1.247 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-19 | 15 | 51.96 | 89.83 | 35.00 | 68.78 |
| Quarter Ending Dec-19 | 15 | 59.10 | 98.42 | 40.90 | 85.59 |
| Year Ending Dec-19 | 18 | 211.55 | 590.20 | 139.20 | 264.51 |
| Year Ending Dec-20 | 17 | 428.75 | 592.61 | 321.00 | 615.32 |
| Earnings (per share) | |||||
| Quarter Ending Sep-19 | 16 | -2.13 | -1.69 | -2.52 | -1.69 |
| Quarter Ending Dec-19 | 16 | -2.36 | -1.82 | -2.95 | -1.68 |
| Year Ending Dec-19 | 16 | -8.22 | -4.82 | -9.49 | -6.39 |
| Year Ending Dec-20 | 15 | -7.27 | -5.99 | -8.80 | -3.57 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 98.31 | 33.85 | |
| P/E High - Last 5 Yrs. | -- | 169.52 | 54.29 | |
| P/E Low - Last 5 Yrs. | -- | 53.54 | 28.22 | |
| Beta | 2.44 | 1.29 | 0.99 | |
| Price to Sales (TTM) | 97.26 | 42.65 | 7.90 | |
| Price to Book (MRQ) | 5.21 | 12.25 | 4.38 | |
| Price to Tangible Book (MRQ) | 5.43 | 17.14 | 5.07 | |
| Price to Cash Flow (TTM) | -- | 64.56 | 23.70 | |
| % Owned Institutions | 89.28 | 3.24 | 1.78 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.11 | 1.67 | |
| Dividend Yield - 5 Year Avg | -- | 0.05 | 1.37 | |
| Dividend 5 Year Growth Rate | -- | 0.86 | 6.82 | |
| Payout Ratio(TTM) | -- | 2.55 | 46.67 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 52.03 | 53.93 | 14.65 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -7.05 | 51.52 | 8.45 | |
| Sales - 5 Yr. Growth Rate | 9.69 | 33.42 | 9.43 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -21.51 | -8.31 | 19.40 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -41.13 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 22.74 | 7.15 | |
| Capital Spending - 5 Yr. Growth Rate | 99.59 | 26.66 | 8.01 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 9.12 | 2.76 | 2.52 |
| Current Ratio (MRQ) | 9.33 | 3.87 | 3.52 |
| LT Debt to Equity (MRQ) | 1.94 | 7.63 | 12.61 |
| Total Debt to Equity (MRQ) | 1.94 | 20.26 | 17.64 |
| Interest Coverage (TTM) | -- | 30.21 | 14.93 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 59.38 | 21.69 | 50.25 | |
| Gross Margin - 5 Yr. Avg. | -- | 58.96 | 51.36 | |
| EBITD Margin (TTM) | -974.00 | -- | -- | |
| EBITD - 5 Yr. Avg | -779.90 | -12.49 | 16.42 | |
| Operating Margin (TTM) | -968.09 | -124.67 | -6.97 | |
| Operating Margin - 5 Yr. Avg. | -796.93 | -28.74 | 11.87 | |
| Pre-Tax Margin (TTM) | -927.68 | -126.48 | -7.30 | |
| Pre-Tax Margin - 5 Yr. Avg. | -774.72 | -34.06 | 15.72 | |
| Net Profit Margin (TTM) | -929.51 | -132.21 | -11.11 | |
| Net Profit Margin - 5 Yr. Avg. | -762.01 | -38.92 | 11.11 | |
| Effective Tax Rate (TTM) | -- | 17.21 | 20.61 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.84 | 24.51 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 81,036 | 10,400,894 | 870,638,159 | |
| Net Income/Employee (TTM) | -753,238 | 2,349,448 | 101,855,832 | |
| Receivable Turnover (TTM) | 2.04 | 12.32 | 5.88 | |
| Inventory Turnover (TTM) | -- | 2.26 | 3.66 | |
| Asset Turnover (TTM) | 0.04 | 0.32 | 0.85 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -40.75 | 6.26 | 10.25 | |
| Return on Assets - 5 Yr. Avg. | -34.42 | 6.14 | 11.17 | |
| Return on Investment (TTM) | -43.69 | 7.52 | 12.69 | |
| Return on Investment - 5 Yr. Avg. | -37.49 | 7.98 | 14.15 | |
| Return on Equity (TTM) | -48.59 | 7.94 | 17.13 | |
| Return on Equity - 5 Yr. Avg. | -40.78 | 8.90 | 15.53 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -16.69 | 22.15 | 9.69 |
| EPS (TTM) % | -39.80 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Alnylam Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 5.24 | 2.31 | 99 | 4 |
| 13 Week | -12.29 | -14.78 | 99 | 7 |
| 26 Week | -8.06 | -19.03 | 99 | 20 |
| 52 Week | -28.33 | -32.80 | 99 | 12 |
| YTD | 4.73 | -13.23 | 99 | 9 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- Regeneron second-quarter revenue beats on Eylea sales
- Pfizer gets U.S. approval for $225,000 a year heart drug
- UPDATE 2-Pfizer gets U.S. approval for $225,000 a year heart drug
- UPDATE 2-Regeneron forays into gene-silencing therapies with Alnylam tie-up
- Alnylam, Regeneron to partner for RNAi treatments
Institutional Holders
| % Shares Owned: | 89.28% |
| # of Holders: | 457 |
| Total Shares Held: | 99,086,245 |
| 3 Mo. Net Change: | 653,644 |
| # New Positions: | 16 |
| # Closed Positions: | 10 |
| # Increased Positions: | 50 |
| # Reduced Positions: | 32 |
| # Net Buyers: | 18 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.